Journal
JOURNAL OF GENERAL INTERNAL MEDICINE
Volume 37, Issue 1, Pages 4-14Publisher
SPRINGER
DOI: 10.1007/s11606-021-07203-8
Keywords
-
Funding
- Red de Apoyo a la Investigacion (RAI)
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Ask authors/readers for more resources
A triple-blind clinical trial was conducted to evaluate the safety and efficacy of colchicine treatment in 116 hospitalized severe COVID-19 patients. The study showed that colchicine had no effect on the primary outcome, days of ICU and hospital stays, and adverse events were similar between the colchicine and placebo groups. After colchicine treatment, patients had higher BUN levels and lower serum levels of IL-8, IL-12p70, and IL-17A.
Background Colchicine is an available, safe, and effective anti-inflammatory drug and has been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID-19 patients has not been thoroughly demonstrated. Objective To address the safety and efficacy of colchicine in hospitalized patients with severe COVID-19. Design We conducted a triple-blind parallel non-stratified placebo-controlled clinical trial. Participants We recruited 116 hospitalized patients with severe COVID-19 in Mexico. Interventions Patients were randomized to receive 1.5 mg of colchicine or placebo at the time of the recruitment in the study (baseline) and 0.5 mg BID PO to complete 10 days of treatment. Main Measures The primary composite outcome was the progression to critical disease or death. Besides, we evaluated immunological features at baseline and after recovery or disease progression in 20 patients. Key Results Fifty-six patients were allocated to colchicine and 60 patients received placebo. The study was suspended after the second interim analysis demonstrated colchicine had no effect on the primary outcome (OR 0.83, 95%CI 0.35-1.93, P = 0.67), nor in the days of ICU and hospital stays. Adverse events were similar between groups (OR 1.63, 95% CI 0.66-3.88, P = 0.37). After colchicine treatment, patients had higher BUN and lower serum levels of IL-8, IL-12p70, and IL-17A. Conclusions Colchicine is safe but not effective in the treatment of severe COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available